Table 2 IDD-3 Administration
N | |
|---|---|
Number of treated patients | 33 |
Total number of doses administered | 243 |
Number of doses administered per patient: | |
Median (range) | 7 (2-14) |
Number of patients with ≥ 6 doses (w0 to w10) | 26 (79%) |
Number of patients with ≥ 8 doses (w0 to w22) | 13 (39%) |
Number of patients discontinuing prior to treatment initiation | 5 (13%) |
Discontinued due to: | |
IDD-3 manufacture failure | 2 (5%) |
Early disease progression | 3 (8%) |